- Home
- BCAL vs SLS Comparison
BCAL vs SLS Comparison
Compare BCAL & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAL | SLS |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 616.3M | 706.7M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BCAL | SLS |
|---|---|---|
| Price | $18.36 | $5.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $20.50 | $7.00 |
| AVG Volume (30 Days) | 187.9K | ★ 5.1M |
| Earning Date | 04-29-2026 | 04-16-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | ★ 1.42 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.35 | N/A |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.88 | $0.95 |
| 52 Week High | $20.47 | $5.18 |
Technical Indicators
Market Signals| Indicator | BCAL | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 68.87 |
| Support Level | $17.80 | $1.48 |
| Resistance Level | $19.31 | N/A |
| Average True Range (ATR) | 0.44 | 0.37 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 39.17 | 92.11 |
Price Performance
Historical ComparisonAbout BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.